Heidelberg, November 2023 – We are thrilled to announce the arrival of Heidelberg Epignostix GmbH, a pioneering force in molecular neuropathology, with a mission to revolutionize cancer diagnostics by applying AI-based approaches for epigenetic tumor classification. Based on an exclusive license to IP from the world-renowned German Cancer Research Center (DKFZ) and University of Heidelberg, the company is pursuing the development of In Vitro Diagnostic (IVD-R) compatible classification tools for brain tumors and other cancer types. We are focused on creating solutions to enable precise diagnoses and personalized care, positioning the company at the forefront of cutting-edge oncology diagnostics.
Unraveling the Complexity of CNS Tumors:
At the heart of our mission lies our sophisticated, peer-reviewed methylation classifier (‘the Heidelberg Classifier’), an innovative solution designed to unravel the intricate molecular signatures within central nervous system (CNS) tumors using advanced data analysis and state-of-the-art machine learning algorithms. The CNS tumor classifier was made publicly available for research use on the Molecular Neuropathology web platform in 2016, and has since seen over 120,000 uploads from across the globe.
Advancing Towards IVD-R Compliance and the CE Mark:
While currently available for research use only, Heidelberg Epignostix is diligently working towards achieving European IVD-R diagnostic certification for its Classifier, to obtain the prestigious CE mark. This goal underscores the company’s unwavering dedication to attaining the highest standards of diagnostic accuracy and reliability.
A Vision for Personalized Care:
Heidelberg Epignostix envisions a future where personalized, data-led diagnostics is accessible to all cancer patients. By aiming for diagnostic certification, the company seeks to support accurate and precise diagnoses using a robust decision-support tool, making optimal personalized care a reality for patients across diverse healthcare settings.
Heidelberg Epignostix is committed to advancing the field of cancer diagnostics with our innovative software solutions for DNA methylation-based tumor classification. Our strong IP portfolio, licensed from the DKFZ and the University of Heidelberg, has been instrumental in our journey towards achieving IVD-R compliance for the most advanced tool in our product range – the internationally respected Heidelberg Brain Tumor Classifier.
Dr David Jones, CEO (Heidelberg Epignostix GmbH)
About Heidelberg Epignostix:
Heidelberg Epignostix GmbH is a pioneering company dedicated combining world-leading scientific and medical expertise with cutting-edge technical innovation, to improve diagnostic accuracy and enhance clinical care in the field of oncology. Our vision is to ensure that all cancer patients are treated optimally and as individuals, by becoming the gold standard for innovative solutions in precision molecular diagnostics.
